Tag: ARBs market research

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Angiotensin Receptor Blockers (ARBs) Market?

The market size for angiotensin receptor blockers (ARBs) has demonstrated consistent growth in recent years. It is anticipated to expand from $8.51 billion in 2024 to $8.78 billion in 2025, at a compound annual growth rate (CAGR) of 3.1%. The growth observed in the historic period is attributable to the hypertension epidemic, their clinical efficacy, the burden of cardiovascular disease, renal protection, supportive clinical guidelines, ARBs being a first-line treatment, and their cost-effectiveness.

The market size for angiotensin receptor blockers (arbs) is anticipated to demonstrate steady expansion over the next few years, projected to reach “$10.52 billion by 2029, at a compound annual growth rate (CAGR) of 4.6%.” This expected growth within the forecast period can be ascribed to several factors, including precision medicine approaches, an increased focus on combination therapies, the global expansion of the market, biomarker-based treatment strategies, government initiatives, and a greater awareness of hypertension. Key trends identified for the forecast period involve the widespread adoption of telemedicine, significant investments in research and development, growing generic competition alongside patent expirations, the deployment of digital health solutions aimed at improving medication adherence, and the rise of biosimilar competition.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which Drivers Are Impacting The Angiotensin Receptor Blockers (ARBs) Market?

The rising occurrence of cardiovascular diseases is anticipated to stimulate the expansion of the angiotensin receptor blockers market moving forward. Cardiovascular disease (CVD) encompasses any ailment affecting the heart or blood vessels, frequently linked to the accumulation of fatty deposits within arteries (atherosclerosis) and a heightened risk of blood clots. Angiotensin receptor blockers function by lowering blood pressure and enhancing the heart’s pumping capability through assisting in vein and artery relaxation, which can diminish the likelihood of cardiovascular disease. For example, in August 2022, according to the American College of Cardiology, a US-based professional medical organization, the projected rates of cardiovascular risk factors and disease are set to significantly increase in the United States by the year 2060. Consequently, the growing incidence of cardiovascular diseases is driving the growth of the angiotensin receptor blockers market.

What Are The Major Segment Types Covered In The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

What Are The Major Trends Driving The Growth Of The Angiotensin Receptor Blockers (ARBs) Market?

Leading companies in the angiotensin receptor blocker market are developing advanced products, such as angiotensin receptor neprilysin inhibitors, to enhance treatment options and improve outcomes for patients with cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) are a class of medications used to treat heart failure. For instance, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, introduced sacubitril + valsartan tablets, which are specialized for the treatment of heart failure, specifically targeting heart failure with reduced ejection fraction (HFrEF). This combination belongs to the class of medications known as ARNI (angiotensin receptor neprilysin inhibitors). Sacubitril works by enhancing the natriuretic peptide (NP) system, which helps alleviate fluid overload and promotes blood vessel dilation, while valsartan blocks the renin-angiotensin system (RAS) to lower blood pressure and reduce the heart’s workload. Together, these components effectively improve heart failure symptoms, lower the risk of cardiovascular mortality, and decrease the chances of hospitalization due to heart failure. They are marketed under the brand name Sacu V.

Who Are The Key Multinational Companies Dominating The Angiotensin Receptor Blockers (ARBs) Market?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Angiotensin Receptor Blockers (ARBs) Market?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Angiotensin Receptor Blockers (ARBs) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

Browse Through More Reports Similar to the Global Angiotensin Receptor Blockers (ARBs) Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Convalescent Plasma Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Patient Blood Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Angiotensin Receptor Blockers (ARBs) Market?

The market for angiotensin receptor blockers (arbs) has seen consistent growth over the past few years. The industry, currently valued at $8.51 billion in 2024, is projected to increase to $8.78 billion in 2025, boasting a compound annual growth rate (CAGR) of 3.1%. This growth during the historical period is consequent of several factors including the widespread hypertension situation, clinical effectiveness, a high prevalence of cardiovascular diseases, renal safeguarding, clinical guidelines, the use of ARBs as a primary treatment option, and cost-effectiveness.

The market size of angiotensin receptor blockers (arbs) is anticipated to experience consistent expansion in the coming years, with projections indicating a growth to “$10.52 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The predicted growth in this period can be linked to precision medicine methods, prioritization of combination therapies, worldwide market expansion, treatment tactics based on biomarkers, government schemes and increased understanding of hypertension. Key trends to watch during this forecast period encompass the incorporation of telemedicine, investment in research and development, the competition from generics and patent expirations, digital health solutions to ensure medication adherence, and competition from biosimilars.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which Key Factors Are Fueling Growth In The Angiotensin Receptor Blockers (ARBs) Market?

The surge in cardiovascular disease incidents is predicted to fuel the advancement of the angiotensin receptor blockers market. Conditions impacting the heart or blood vessels are classified as cardiovascular diseases (CVD). They often coincide with the evolution of fatty residue in the arteries (atherosclerosis), accelerating the probability of blood clots. Angiotensin receptor blockers alleviate blood pressure and enhance the heart’s blood pumping capability by facilitating the relaxation of veins and arteries, thereby reducing the likelihood of cardiovascular diseases. For example, the American College of Cardiology, a US-based healthcare professional institution, projected in August 2022 that the prevalence of cardiovascular risk determinants and diseases will significantly escalate in the United States towards 2060. Hence, the escalating prevalence of cardiovascular diseases is propelling the angiotensin receptor blockers market’s expansion.

What Segmentation Insights Are Provided In The Angiotensin Receptor Blockers (ARBs) Market Research?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

Which Notable Trends Are Transforming The Angiotensin Receptor Blockers (ARBs) Market Outlook?

Leading businesses operating in the angiotensin receptor blocker market are creating advanced products like angiotensin receptor neprilysin inhibitors, to broaden treatment possibilities and enhance patient outcomes in cardiovascular diseases. Medications known as angiotensin receptor neprilysin inhibitors (ARNIs) are utilized in heart failure treatment. For example, in January 2023, Glenmark Pharmaceuticals, a pharmaceutical firm based in India, introduced sacubitril + valsartan tablets tailored for heart failure treatment, specifically for heart failure with reduced ejection fraction (HFrEF). This combination is categorized as ARNI (angiotensin receptor neprilysin inhibitors). Sacubitril enhances the natriuretic peptide system, which helps in fluid overload relief and blood vessel expansion, while valsartan inhibits the renin-angiotensin system (RAS) to decrease blood pressure and reduce stress on the heart. When combined, these effectively alleviate heart failure symptoms, decrease the risk of cardiovascular death, and lower hospitalization rates due to heart failure. These products are sold under the brand name Sacu V.

Who Are The Major Stakeholders Operating In The Angiotensin Receptor Blockers (ARBs) Market?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Angiotensin Receptor Blockers (ARBs) Market?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Angiotensin Receptor Blockers (ARBs) Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market size of angiotensin receptor blockers (arbs) has been on a steady increase. Estimates see it rising from $8.51 billion in 2024 to $8.78 billion in 2025 with a compound annual growth rate (CAGR) of 3.1%. Factors such as an increase in hypertension cases, clinical efficacy, the burden of cardiovascular disease, renal protection, clinical guidelines, and the use of ARBs as first-line treatment, coupled with their cost-effectiveness, account for the growth during the historic period.

The market for angiotensin receptor blockers (arbs) is slated to experience a consistent rise in the coming years, with projections suggesting it will attain a valuation of “$10.52 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.6%.” Factors contributing to this uptick include precision medicine tactics, a focus on amalgamated treatments, wider worldwide market reach, treatment avenues based on biomarkers, governmental programs, and increased hypertension awareness. The forecast period will also see prevailing trends including the adoption of telemedicine, increase in research and development expenditures, intensifying generic competition and patent expirations, digitization of medication adherence solutions, and competition from biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What factors are expected to fuel Angiotensin Receptor Blockers (ARBs) market growth in the coming years?

The angiotensin receptor blockers market is poised for growth, propelled by the rising incidences of cardiovascular ailments. Cardiovascular disease (CVD) encompasses any conditions which impact the heart or blood vessels and is frequently linked with the buildup of fatty deposits in the arteries (atherosclerosis) and an elevated risk of blood clots. The function of angiotensin receptor blockers is to reduce blood pressure and enhance the ability of the heart to pump blood by aiding in the relaxation of arteries and veins, subsequently reducing the risk of cardiovascular disease. As per the American College of Cardiology, a professional medical organization based in the US, indications show a significant predicted increase in cardiovascular risk factors and disease prevalence by 2060 in the country. Therefore, the escalating occurrence of cardiovascular diseases is a driving factor for the expansion of the angiotensin receptor blockers market.

What Are The Key Findings From The Segmentation Analysis Of The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

How Are Key Trends Driving Expansion In The Angiotensin Receptor Blockers (ARBs) Industry?

Leading companies in the angiotensin receptor blocker market are innovating advanced products such as angiotensin receptor neprilysin inhibitors, to increase treatment options and better patient outcomes for cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) represent a category of medicines designed to manage heart failure. For example, Glenmark Pharmaceuticals, a pharmaceutical company based in India, debuted sacubitril + valsartan tablets in January 2023. These tablets are specifically made to treat heart failure, with a particular focus on heart failure with reduced ejection fraction (HFrEF). This product blend is part of the ARNI (angiotensin receptor neprilysin inhibitors) medication class. Sacubitril boosts the natriuretic peptide (NP) system, which helps in reducing fluid overload and supporting blood vessel expansion, while valsartan inhibits the renin-angiotensin system (RAS), reducing blood pressure and lightening the load on the heart. Collectively, they enhance heart failure symptoms management, decrease the likelihood of cardiovascular death, and lower the risk of hospital admissions related to heart failure. These tablets are sold under the Sacu V brand name.

What Are The Most Active Companies In The Angiotensin Receptor Blockers (ARBs) Market Today?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Regional Markets Are Attracting The Most Investment In Angiotensin Receptor Blockers (ARBs)?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Angiotensin Receptor Blockers (ARBs) Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market size of angiotensin receptor blockers (arbs) has been on a steady increase. Estimates see it rising from $8.51 billion in 2024 to $8.78 billion in 2025 with a compound annual growth rate (CAGR) of 3.1%. Factors such as an increase in hypertension cases, clinical efficacy, the burden of cardiovascular disease, renal protection, clinical guidelines, and the use of ARBs as first-line treatment, coupled with their cost-effectiveness, account for the growth during the historic period.

The market for angiotensin receptor blockers (arbs) is slated to experience a consistent rise in the coming years, with projections suggesting it will attain a valuation of “$10.52 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.6%.” Factors contributing to this uptick include precision medicine tactics, a focus on amalgamated treatments, wider worldwide market reach, treatment avenues based on biomarkers, governmental programs, and increased hypertension awareness. The forecast period will also see prevailing trends including the adoption of telemedicine, increase in research and development expenditures, intensifying generic competition and patent expirations, digitization of medication adherence solutions, and competition from biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What factors are expected to fuel Angiotensin Receptor Blockers (ARBs) market growth in the coming years?

The angiotensin receptor blockers market is poised for growth, propelled by the rising incidences of cardiovascular ailments. Cardiovascular disease (CVD) encompasses any conditions which impact the heart or blood vessels and is frequently linked with the buildup of fatty deposits in the arteries (atherosclerosis) and an elevated risk of blood clots. The function of angiotensin receptor blockers is to reduce blood pressure and enhance the ability of the heart to pump blood by aiding in the relaxation of arteries and veins, subsequently reducing the risk of cardiovascular disease. As per the American College of Cardiology, a professional medical organization based in the US, indications show a significant predicted increase in cardiovascular risk factors and disease prevalence by 2060 in the country. Therefore, the escalating occurrence of cardiovascular diseases is a driving factor for the expansion of the angiotensin receptor blockers market.

What Are The Key Findings From The Segmentation Analysis Of The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

How Are Key Trends Driving Expansion In The Angiotensin Receptor Blockers (ARBs) Industry?

Leading companies in the angiotensin receptor blocker market are innovating advanced products such as angiotensin receptor neprilysin inhibitors, to increase treatment options and better patient outcomes for cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) represent a category of medicines designed to manage heart failure. For example, Glenmark Pharmaceuticals, a pharmaceutical company based in India, debuted sacubitril + valsartan tablets in January 2023. These tablets are specifically made to treat heart failure, with a particular focus on heart failure with reduced ejection fraction (HFrEF). This product blend is part of the ARNI (angiotensin receptor neprilysin inhibitors) medication class. Sacubitril boosts the natriuretic peptide (NP) system, which helps in reducing fluid overload and supporting blood vessel expansion, while valsartan inhibits the renin-angiotensin system (RAS), reducing blood pressure and lightening the load on the heart. Collectively, they enhance heart failure symptoms management, decrease the likelihood of cardiovascular death, and lower the risk of hospital admissions related to heart failure. These tablets are sold under the Sacu V brand name.

What Are The Most Active Companies In The Angiotensin Receptor Blockers (ARBs) Market Today?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Regional Markets Are Attracting The Most Investment In Angiotensin Receptor Blockers (ARBs)?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Angiotensin Receptor Blockers (ARBs) Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market size of angiotensin receptor blockers (arbs) has been on a steady increase. Estimates see it rising from $8.51 billion in 2024 to $8.78 billion in 2025 with a compound annual growth rate (CAGR) of 3.1%. Factors such as an increase in hypertension cases, clinical efficacy, the burden of cardiovascular disease, renal protection, clinical guidelines, and the use of ARBs as first-line treatment, coupled with their cost-effectiveness, account for the growth during the historic period.

The market for angiotensin receptor blockers (arbs) is slated to experience a consistent rise in the coming years, with projections suggesting it will attain a valuation of “$10.52 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.6%.” Factors contributing to this uptick include precision medicine tactics, a focus on amalgamated treatments, wider worldwide market reach, treatment avenues based on biomarkers, governmental programs, and increased hypertension awareness. The forecast period will also see prevailing trends including the adoption of telemedicine, increase in research and development expenditures, intensifying generic competition and patent expirations, digitization of medication adherence solutions, and competition from biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What factors are expected to fuel Angiotensin Receptor Blockers (ARBs) market growth in the coming years?

The angiotensin receptor blockers market is poised for growth, propelled by the rising incidences of cardiovascular ailments. Cardiovascular disease (CVD) encompasses any conditions which impact the heart or blood vessels and is frequently linked with the buildup of fatty deposits in the arteries (atherosclerosis) and an elevated risk of blood clots. The function of angiotensin receptor blockers is to reduce blood pressure and enhance the ability of the heart to pump blood by aiding in the relaxation of arteries and veins, subsequently reducing the risk of cardiovascular disease. As per the American College of Cardiology, a professional medical organization based in the US, indications show a significant predicted increase in cardiovascular risk factors and disease prevalence by 2060 in the country. Therefore, the escalating occurrence of cardiovascular diseases is a driving factor for the expansion of the angiotensin receptor blockers market.

What Are The Key Findings From The Segmentation Analysis Of The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

How Are Key Trends Driving Expansion In The Angiotensin Receptor Blockers (ARBs) Industry?

Leading companies in the angiotensin receptor blocker market are innovating advanced products such as angiotensin receptor neprilysin inhibitors, to increase treatment options and better patient outcomes for cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) represent a category of medicines designed to manage heart failure. For example, Glenmark Pharmaceuticals, a pharmaceutical company based in India, debuted sacubitril + valsartan tablets in January 2023. These tablets are specifically made to treat heart failure, with a particular focus on heart failure with reduced ejection fraction (HFrEF). This product blend is part of the ARNI (angiotensin receptor neprilysin inhibitors) medication class. Sacubitril boosts the natriuretic peptide (NP) system, which helps in reducing fluid overload and supporting blood vessel expansion, while valsartan inhibits the renin-angiotensin system (RAS), reducing blood pressure and lightening the load on the heart. Collectively, they enhance heart failure symptoms management, decrease the likelihood of cardiovascular death, and lower the risk of hospital admissions related to heart failure. These tablets are sold under the Sacu V brand name.

What Are The Most Active Companies In The Angiotensin Receptor Blockers (ARBs) Market Today?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Regional Markets Are Attracting The Most Investment In Angiotensin Receptor Blockers (ARBs)?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Angiotensin Receptor Blockers (ARBs) Market Evolve in Terms of Growth and Size by 2029?

The market size for Angiotensin Receptor Blockers (ARBS) has seen consistent growth in recent years. From $8.51 billion in 2024, it is predicted to expand to $8.78 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of 3.1%. Factors such as the increasing prevalence of hypertension, the proven clinical efficacy of ARBs, burden of cardiovascular disease, renal protection, clinical guidelines, the preference for ARBs as a frontline treatment, and their cost-effectiveness have all contributed to growth during the historic period.

The market size for angiotensin receptor blockers (arbs) is anticipated to see a consistent surge in growth over the next few years. This market is projected to expand to $10.52 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 4.6%. The expansion during the forecasted period can be credited to factors such as precision medicine methodologies, emphasis on combination therapies, worldwide market expansion, strategies based on biomarker treatment, governmental initiatives, and heightened awareness about hypertension. The forecast period will also see major trends like the adoption of telemedicine, investment in research and development, competition from generic drugs and patent terminations, digital health tools to enhance medication adherence, and competition from biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What factors are expected to fuel Angiotensin Receptor Blockers (ARBs) market growth in the coming years?

The growth of the angiotensin receptor blockers market is anticipated to be boosted by the rising prevalence of cardiovascular diseases. Cardiovascular disease (CVD), a condition that impacts the heart or blood vessels, often correlates with the formation of fatty deposits within the arteries (atherosclerosis) and a heightened risk of blood clots. Angiotensin receptor blockers, which lower blood pressure and enhance the heart’s ability to circulate blood by aiding in the relaxation of veins and arteries, can help reduce the risk of cardiovascular disease. As an example, the American College of Cardiology, a professional medical organization in the U.S., projected in August 2022 that the rates of cardiovascular risk factors and illnesses would see a significant increase in the United States by 2060. Consequently, the escalating prevalence of cardiovascular diseases is stimulating the angiotensin receptor blockers market’s growth.

What Are The Key Findings From The Segmentation Analysis Of The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

Which Trends Are Expected To Shape The Future Of The Angiotensin Receptor Blockers (ARBs) Market?

Leading firms in the angiotensin receptor blocker market are innovating with sophisticated products such as angiotensin receptor neprilysin inhibitors to augment treatment alternatives and boost patient outcomes for cardiovascular diseases. These inhibitors, known as ARNIs, are a category of drugs applied in heart failure treatment. For instance, Glenmark Pharmaceuticals, an Indian company, introduced sacubitril + valsartan tablets in January 2023, a specialized treatment for heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combination is classified under ARNI medications. Sacubitril amplifies the natriuretic peptide (NP) system to relieve fluid overload and foster blood vessel expansion, while valsartan restricts the renin-angiotensin system (RAS) to reduce blood pressure and minimize the workload of the heart. Together, both components enhance heart failure symptoms, lower the risk of cardiovascular death, and shrink the likelihood of heart failure-related hospitalizations. They are sold under the brand name Sacu V.

What Are The Most Active Companies In The Angiotensin Receptor Blockers (ARBs) Market Today?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Regional Markets Are Attracting The Most Investment In Angiotensin Receptor Blockers (ARBs)?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Angiotensin Receptor Blockers (ARBs) Market Size Changed, over the years?

The market size for angiotensin receptor blockers (ARBs) has seen consistent growth in the past few years. The market is expected to increase from $8.51 billion in 2024 to $8.87 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.1%. Factors such as the widespread prevalence of hypertension, clinical effectiveness, the high burden of cardiovascular disease, renal protective qualities, established clinical guidelines, the positioning of ARBs as a first-line treatment, and cost-effectiveness have contributed to the growth during the historical period.

How Much Will the Angiotensin Receptor Blockers (ARBs) Market Be Worth in 2029?

In the coming years, the market size for Angiotensin receptor blockers (ARBs) is projected to experience a steady growth, eventually reaching approximately $10.76 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. The expected growth within the forecast period can be ascribed to the adoption of precision medicine approaches, emphasis on combination therapies, global market expansion, biomarker-centric treatment tactics, government initiatives, and a heightened awareness of hypertension. Within the forecast period, significant trends are anticipated to include the adoption of telemedicine, investment in research and development, generic competition accompanied by patent expirations, tech-driven solutions for medication adherence, and competition from biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which is the Largest Company in the Angiotensin Receptor Blockers (ARBs) Market?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

What Are the Main Market Drivers in the Angiotensin Receptor Blockers (ARBs) Industry?

The surge in cardiovascular diseases is anticipated to boost the expansion of the angiotensin receptor blockers market. Cardiovascular disease, which affects the heart or blood vessels, commonly involves the buildup of fatty deposits in the arteries, also known as atherosclerosis, leading to a heightened risk of blood clots. Angiotensin receptor blockers, which aid in the relaxation of veins and arteries, have been found to lower blood pressure and enhance the heart’s blood pumping ability, thereby reducing the risk of cardiovascular disease. In a forecast by the American College of Cardiology, a professional medical organization based in the US, in August 2022, it was revealed that the incidence of cardiovascular risk factors and disease in the United States is set to rise significantly by 2060. Consequently, the escalating prevalence of cardiovascular diseases is fuelling the growth of the angiotensin receptor blockers market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

How Is the Angiotensin Receptor Blockers (ARBs) Market Segments Structured?

The angiotensin receptor blockers (ARBs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

What Strategic Trends Are Transforming the Angiotensin Receptor Blockers (ARBs) Market?

Leading players in the angiotensin receptor blocker market are forging ahead with innovative products such as angiotensin receptor neprilysin inhibitors. These new developments aim to broaden treatment alternatives and yield better results for patients coping with cardiovascular illnesses. Angiotensin receptor neprilysin inhibitors (ARNIs) stand as a vital medication subset for the treatment of heart failure. For example, in January 2023, sacubitril + valsartan tablets were introduced into the market by Glenmark Pharmaceuticals, a firm based in India, targeting specifically heart failure with reduced ejection fraction (HFrEF). This combination belongs to ARNI, a lineup of medications known for this action. Sacubitril boosts the natriuretic peptide (NP) system, leading to fluid overload reduction and enhanced blood vessel dilation, whereas valsartan restricts the renin-angiotensin system (RAS), decreasing both blood pressure and the heart’s work output. When combined, they provide an effective mitigation strategy for heart failure symptoms, a lowered cardiovascular death risk, and a decrease in hospitalization due to heart failure. These tablets are sold under the brand Sacu V.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Global Regions Offer the Highest Growth in the Angiotensin Receptor Blockers (ARBs) Market?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943

This Report Delivers Insight On:

1. How big is the angiotensin receptor blockers (arbs) market, and how is it changing globally?

2. Who are the major companies in the angiotensin receptor blockers (arbs) market, and how are they performing?

3. What are the key opportunities and risks in the angiotensin receptor blockers (arbs) market right now?

4. Which products or customer segments are growing the most in the angiotensin receptor blockers (arbs) market?

5. What factors are helping or slowing down the growth of the angiotensin receptor blockers (arbs) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Angiotensin Receptor Blockers (ARBs) Market Size Changed, over the years?

The market size for angiotensin receptor blockers (ARBs) has seen consistent growth in the past few years. The market is expected to increase from $8.51 billion in 2024 to $8.87 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.1%. Factors such as the widespread prevalence of hypertension, clinical effectiveness, the high burden of cardiovascular disease, renal protective qualities, established clinical guidelines, the positioning of ARBs as a first-line treatment, and cost-effectiveness have contributed to the growth during the historical period.

How Much Will the Angiotensin Receptor Blockers (ARBs) Market Be Worth in 2029?

In the coming years, the market size for Angiotensin receptor blockers (ARBs) is projected to experience a steady growth, eventually reaching approximately $10.76 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. The expected growth within the forecast period can be ascribed to the adoption of precision medicine approaches, emphasis on combination therapies, global market expansion, biomarker-centric treatment tactics, government initiatives, and a heightened awareness of hypertension. Within the forecast period, significant trends are anticipated to include the adoption of telemedicine, investment in research and development, generic competition accompanied by patent expirations, tech-driven solutions for medication adherence, and competition from biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which is the Largest Company in the Angiotensin Receptor Blockers (ARBs) Market?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

What Are the Main Market Drivers in the Angiotensin Receptor Blockers (ARBs) Industry?

The surge in cardiovascular diseases is anticipated to boost the expansion of the angiotensin receptor blockers market. Cardiovascular disease, which affects the heart or blood vessels, commonly involves the buildup of fatty deposits in the arteries, also known as atherosclerosis, leading to a heightened risk of blood clots. Angiotensin receptor blockers, which aid in the relaxation of veins and arteries, have been found to lower blood pressure and enhance the heart’s blood pumping ability, thereby reducing the risk of cardiovascular disease. In a forecast by the American College of Cardiology, a professional medical organization based in the US, in August 2022, it was revealed that the incidence of cardiovascular risk factors and disease in the United States is set to rise significantly by 2060. Consequently, the escalating prevalence of cardiovascular diseases is fuelling the growth of the angiotensin receptor blockers market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

How Is the Angiotensin Receptor Blockers (ARBs) Market Segments Structured?

The angiotensin receptor blockers (ARBs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

What Strategic Trends Are Transforming the Angiotensin Receptor Blockers (ARBs) Market?

Leading players in the angiotensin receptor blocker market are forging ahead with innovative products such as angiotensin receptor neprilysin inhibitors. These new developments aim to broaden treatment alternatives and yield better results for patients coping with cardiovascular illnesses. Angiotensin receptor neprilysin inhibitors (ARNIs) stand as a vital medication subset for the treatment of heart failure. For example, in January 2023, sacubitril + valsartan tablets were introduced into the market by Glenmark Pharmaceuticals, a firm based in India, targeting specifically heart failure with reduced ejection fraction (HFrEF). This combination belongs to ARNI, a lineup of medications known for this action. Sacubitril boosts the natriuretic peptide (NP) system, leading to fluid overload reduction and enhanced blood vessel dilation, whereas valsartan restricts the renin-angiotensin system (RAS), decreasing both blood pressure and the heart’s work output. When combined, they provide an effective mitigation strategy for heart failure symptoms, a lowered cardiovascular death risk, and a decrease in hospitalization due to heart failure. These tablets are sold under the brand Sacu V.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Global Regions Offer the Highest Growth in the Angiotensin Receptor Blockers (ARBs) Market?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943

This Report Delivers Insight On:

1. How big is the angiotensin receptor blockers (arbs) market, and how is it changing globally?

2. Who are the major companies in the angiotensin receptor blockers (arbs) market, and how are they performing?

3. What are the key opportunities and risks in the angiotensin receptor blockers (arbs) market right now?

4. Which products or customer segments are growing the most in the angiotensin receptor blockers (arbs) market?

5. What factors are helping or slowing down the growth of the angiotensin receptor blockers (arbs) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the angiotensin receptor blockers (arbs) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Anticipated CAGR of the Angiotensin Receptor Blockers (ARBs) Market, and What Factors Will Drive It?

In recent times, there’s been a steady rise in the market size of angiotensin receptor blockers (ARBs). Its growth is predicted to increase from $8.51 billion in 2024 to $8.87 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.1%. The historical growth of this market can be traced back to the epidemic of hypertension, efficacy in clinical trials, high burden of cardiovascular diseases, protection of renal health, clinical guidelines, the trend of using ARBs as the first line of treatment, and its cost-effectiveness.

The market for angiotensin receptor blockers (ARBs) is anticipated to experience consistent expansion in the coming years, reaching a value of $10.76 billion in 2029, with a compound annual growth rate (CAGR) of 5.0%. This growth forecast can be attributed to several factors including the adoption of precision medicine, a focus on combination therapies, global market expansion, the use of biomarker-based treatment methods, government initiatives, and heightened hypertension awareness. The forecast period is also expected to see trends such as the adoption of telemedicine, increased investments in research and development, competition from generic brands and patent expirations, the use of digital health solutions to increase medication adherence, and competition from biosimilars.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Angiotensin Receptor Blockers (ARBs) Market?

The growth of the angiotensin receptor blockers market is anticipated to be driven by the escalating occurrence of cardiovascular diseases. Any condition that impacts the heart or blood vessels is defined as cardiovascular disease (CVD). Often, it’s linked with the manifestation of fatty accumulations within the arteries (atherosclerosis) and an escalated probability of blood clots. Angiotensin receptor blockers are known to decrease blood pressure and enhance the heart’s ability to circulate blood by aiding in the relaxation of veins and arteries. This can potentially reduce the cardiovascular disease risk. For example, the American College of Cardiology, a professional medical organization based in the US, predicted in August 2022, that there will be a significant increase in cardiovascular risk factors and disease in the United States by 2060. Therefore, the mounting prevalence of cardiovascular diseases is fueling the expansion of the angiotensin receptor blockers market.

Which Key Market Segments Comprise the Angiotensin Receptor Blockers (ARBs) Market and Drive Its Revenue Growth?

The angiotensin receptor blockers (ARBs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

Which Areas Are Leading Regions in the Angiotensin Receptor Blockers (ARBs) Market Expansion Across the Globe?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering theAngiotensin Receptor Blockers (ARBs) Market Direction?

Leading firms within the angiotensin receptor blocker market are pursuing the creation of sophisticated offerings such as angiotensin receptor neprilysin inhibitors to expand therapeutic resources and improve patient outcomes with cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) serve as a medication class for managing heart failure. Take, for instance, Glenmark Pharmaceuticals, a pharmaceutical company based in India, which, in January 2023, initiated the distribution of sacubitril + valsartan tablets. These tablets are designed specifically to tackle heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combined medication belongs to the ARNI (angiotensin receptor neprilysin inhibitors) category. Sacubitril boosts the natriuretic peptide (NP) system to relieve fluid overload and facilitate blood vessel expansion. Simultaneously, valsartan inhibits the renin-angiotensin system (RAS), reducing blood pressure and lightening the load on the heart. Collectively, these drugs alleviate symptoms of heart failure, curtail the probability of cardiovascular death, and diminish the likelihood of heart failure hospital admissions. They are sold under the brand name Sacu V.

View the full report here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

How Is the Angiotensin Receptor Blockers (ARBs) Market Conceptually Defined?

Angiotensin receptor blockers (ARBs) are medications that dilate (widen) blood vessels and are used to treat conditions such as high blood pressure (hypertension), heart failure, and kidney disease in people with diabetes. Angiotensin is a chemical in the body that causes blood vessels to constrict. This constriction can raise the blood pressure and make the heart work harder.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of theAngiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers market is predicted to grow due to the rise in cardiovascular diseases. Cardiovascular diseases, conditions that impact the heart or blood vessels, often lead to fatty deposits within arteries (atherosclerosis) and a higher chance of blood clots. Angiotensin receptor blockers help lower blood pressure and enhance the heart’s ability to pump blood because they facilitate the relaxation of veins and arteries—this can reduce the risk of cardiovascular disease. For example, the American College of Cardiology, a professional medical institution based in the US, projected in August 2022 that the prevalence of cardiovascular risk factors and disease will substantially increase in the United States by 2060. As such, the escalating rates of cardiovascular diseases are stimulating the expansion of the angiotensin receptor blockers market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What is the Predicted Annual Growth Rate of theAngiotensin Receptor Blockers (ARBs) Market Impact Industry Trends by 2034?

In recent times, there has been a constant growth in the market size of angiotensin receptor blockers (ARBs). It’s projected to expand from a value of $8.51 billion in 2024 to around $8.87 billion in 2025, marking a compound annual growth rate (CAGR) of 4.1%. This substantial growth in the historical period is linked to various factors including the hypertension epidemic, clinical effectiveness, the burden of cardiovascular disease, renal protection, established clinical guidelines, the usage of ARBs as the initial treatment strategy, and their cost-effectiveness.

The market for angiotensin receptor blockers (ARBs) is predicted to experience consistent growth in the forthcoming years, reaching a value of $10.76 billion in 2029 with a compound annual growth rate (CAGR) of 5.0%. Factors contributing to this growth during the projection period include the adoption of precision medicine tactics, the promotion of combination therapies, the worldwide market expansion, the implementation of biomarker-related treatment strategies, government policies, and enhanced hypertension awareness. The forecast period will be marked by several key trends including the increased use of telemedicine, investment in research and development, competition from generic brands and patent terminations, the use of digital health tools to ensure medication compliance, and competition from biosimilars.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943

How Are Consumer Market Innovations Shaping the Current and Future Landscape of theAngiotensin Receptor Blockers (ARBs) Market?

In the angiotensin receptor blocker market, top-tier companies are focusing on the creation of advanced products such as angiotensin receptor neprilysin inhibitors (ARNIs) to improve treatment choices and patient outcomes related to cardiovascular disorders. ARNIs are a type of drug often used to manage heart failure symptoms. For instance, in January 2023, Glenmark Pharmaceuticals, a pharmaceutical firm based in India, launched a product called sacubitril + valsartan tablets. These tablets are designed to treat heart failure, more specifically heart failure with reduced ejection fraction (HFrEF). This pairing falls under the ARNI category. Sacubitril improves the performance of the natriuretic peptide (NP) system, which reduces fluid overload and enables blood vessel dilation. Meanwhile, valsartan inhibits the renin-angiotensin system (RAS), resulting in lower blood pressure and a lighter workload for the heart. Together, these drugs not only improve symptoms of heart failure, but also diminish the risk of cardiovascular death and decrease the likelihood of being hospitalized due to heart failure. It is sold under the brand name Sacu V.

Who Are the Key Market Players Influencing the Growth of the Corn and Angiotensin Receptor Blockers (ARBs) Industry?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Key Market Segments Comprise the Angiotensin Receptor Blockers (ARBs) Market and Drive Its Revenue Growth?

The angiotensin receptor blockers (ARBs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smpGlobal Angiotensin Receptor Blockers (ARBs) Market, Global Angiotensin Receptor Blockers (ARBs) Market Report, Global Angiotensin Receptor Blockers (ARBs) Market Trends, Global Angiotensin Receptor Blockers (ARBs) Market Size

Browse Through More Reports Similar to the Gobal Angiotensin Receptor Blockers (ARBs) Maret 2025, By The Business Research Company:

Cold Plasma Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cold-plasma-global-market-report

Porcine Plasma Feed Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/porcine-plasma-feed-global-market-report

Mycoplasma Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: